Clinical studies on trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive brain metastases Several previous clinical studies have suggested significant intracranial activity of trastuzumab derux...Clinical studies on trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive brain metastases Several previous clinical studies have suggested significant intracranial activity of trastuzumab deruxtecan(T-DXd)in brain metastases(BMs)of human epidermal growth factor receptor 2(HER2)-positive(HER2-positive)metastatic breast cancer(mBC).Pooled analyses from DESTINY-Breast(DB)01,02,and 03 showed that T-DXd outperformed controls in terms of intracranial overall response rate(ORR)and median progression-free survival(mPFS).展开更多
基金supported by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2023-JKCS-23)the Special Research Fund for Central Universities,Peking Union Medical College(No.2022-I2M-C&T-A-014).
文摘Clinical studies on trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive brain metastases Several previous clinical studies have suggested significant intracranial activity of trastuzumab deruxtecan(T-DXd)in brain metastases(BMs)of human epidermal growth factor receptor 2(HER2)-positive(HER2-positive)metastatic breast cancer(mBC).Pooled analyses from DESTINY-Breast(DB)01,02,and 03 showed that T-DXd outperformed controls in terms of intracranial overall response rate(ORR)and median progression-free survival(mPFS).
